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ABSTRACT (248 words)  
The history of newborn screening (NBS) for neuromuscular disorders began in 1975 with 
screening male infants for Duchenne Muscular Dystrophy (DMD) by measuring creatinine 
kinase on the newborn blood spots from two Midwestern hospitals in the United States 
(US). Over the next 40 years, 10 programs were implemented around the globe, although only 
one country continues to do so.  The longest running program was in Wales (1990-2011) and it 
collected both clinical as well as psychosocial data.  In the last 2 decades, two other 
neuromuscular disorders have been proposed for NBS: Pompe Disease and Spinal Muscular 
Atrophy (SMA). The first pilot program for Pompe Disease began in 2005 in Taiwan and it was 
adopted into their national NBS program in 2008.  Missouri was the first US state to implement 
Pompe NBS and, with its inclusion in the Recommended Universal Screening Panel by the 
Advisory Committee on Heritable Disorders in Newborns and Children (US) in 2015, other 
states will follow quickly. The only pilot SMA NBS program to date was scheduled for Utah and 
Colorado, but in the end recruitment occurred only in Utah, recruitment was slow, and no data 
have been released to-date. In this manuscript, we argue that there are lessons to be learned from 
the Wales DMD program that could benefit the US public health departments as they develop 
screening protocols for neuromuscular disorders like DMD, Pompe and SMA.  We argue that 
screening for all three conditions challenge traditional screening criteria and should require 
parental permission. 
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 Introduction 
Traditionally, the main justification for adding a condition to a state newborn screening 
(NBS) panel was to identify a disorder that would present in infancy for which early intervention 
was necessary to reduce morbidity or mortality. The criteria for such public health screening 
were first enumerated by Wilson and Jungner in 1968,[1] but many other advisory committees in 
the United States [US] [2-11] and around the world [12-19] have come to similar conclusions. 
These criteria include the need for an easy, cheap and accurate screening test, an accurate and 
available diagnostic test, and an effective treatment.  Despite broad consensus in both US and 
international statements that screening requires parental permission, there is disagreement about 
whether screening should be opt-in versus opt-out and whether it should require written 
permission.  In the US, NBS is mandatory, although most states allow parents to opt-out. 
In the US, NBS is a state function. Historically, states varied in the conditions for which they 
screened, whether they routinely performed a second screen, and the methodology and cut-offs 
they used for declaring a screening test to be positive.  In 2005, the US Department of Health and 
Human Services’ (HHS) Advisory Committee for Heritable Disorders in Newborns and Children 
(ACHDNC) was established to promote equity between state newborn screening (NBS) panels, 
amongst other goals.[20] In 2006, the ACHDNC recommended that all states adopt a uniform 
screening panel of 29 primary conditions that was developed by the American College of 
Medical Genetics (now the American College of Medical Genetics and Genomics) in 
collaboration with the Health Resources and Services Administration.[21] Although adoption of 
the conditions in the recommended uniform screening panel (RUSP) into state NBS panels is 
voluntary, all states adopted the initial recommendations and conditions added to the RUSP more 
recently are being adopted, albeit at different speeds by different states.  
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Three neuromuscular conditions--Duchenne Muscular Dystrophy (DMD), Pompe Disease, 
and Spinal Muscular Atrophy (SMA)--have been proposed for the RUSP by advocates in the US, 
although only Pompe is currently included. In this manuscript, we examine in detail the NBS 
programs that have existed for these three neuromuscular disorders. These conditions differ in 
their age of presentation, their symptomatology, and their treatability. We argue that each 
challenges public health screening criteria and, therefore, should not be included in mandatory 
screening programs. However, there are clinical, social and reproductive reasons why some 
parents may want this information early and why some states may be willing to offer it. As such 
it may be appropriate to offer these conditions but to require parental permission to opt-in to 
testing in contrast with current mandatory practices that are best described as opt-out. A tiered 
approach has been supported by the Task Force on Genetic Screening,[5]  the American 
Academy of Pediatrics (AAP) Newborn Screening Task Force,[6] and the President’s Council on 
Bioethics.[8] The main benefit of the tiered approach is its acknowledgment that the clinical 
benefits and risks provided by screening vary between conditions and that screening that 
provides great benefit and low risk to the child (tier one) should be highly encouraged whereas 
greater parental discretion should be given to screening for conditions (tier two) in which 1) 
treatment is not needed urgently or is not highly effective; or 2) symptoms may not present for 
months to years. We argue that the three neuromuscular conditions are most appropriately 
included in the second tier.  We further argue that, if second tier screening is offered, a 
coordinated infrastructure and social support program are needed to support those families who 
receive a positive diagnosis, particularly for conditions where there may be a significant time 
delay between recognition through screening and clinical presentation. 
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Duchenne Muscular Dystrophy (DMD) 
DMD is an X-linked neuromuscular disorder characterized by progressive muscle 
weakness, mainly in boys. A major reason to support screening is to avoid the diagnostic delay 
that frequently occurs.  The mean delay between presentation to a health professional and   
diagnosis around the globe has consistently been approximately 2 years.[22-25] This diagnostic 
odyssey is in itself distressing,[25-28] and also prevents parents from accessing genetic 
counselling and prenatal diagnosis in future pregnancies. More recently, late diagnoses may have 
inappropriately delayed timely access to steroids that prolong ambulation.[28] 
In 1975, Zellweger and Antonik described screening 1,500 male infants for DMD by 
measuring creatinine kinase (CK) in the newborn blood spots from two Midwestern hospitals in 
the United States.[29] Having established the proof of principle of CK testing on dried blood 
spots, the first NBS program for DMD began in New Zealand in 1979.[30]  Ten thousand boys 
were screened and 2 cases of DMD were identified. Programs in Edinburgh, West Germany, 
Canada, France, Belgium and Cyprus followed.[31] In 1991, Naylor of Pittsburgh PA (US) 
reported screening approximately 73,000 newborns, including 20,000 specimens from Sao Paulo, 
Brazil. What was unique to this program was the goal “to provide rapid confirmation of the 
diagnosis as early as possible,” by using “multiplex PCR amplification of DNA from the initial 
filter paper blood specimens.”[32 at p. 23]  
But  concern about late diagnoses must be balanced by concern about the potential for 
parental distress and family disruption that might result from identifying pre-symptomatic 
infants.[33-35] To mitigate the delayed diagnosis/diagnostic odyssey without causing the 
potentially damaging consequences of screening in the newborn period, a study in Wales 
attempted to identify boys with DMD by targeting boys not walking when they reached 18 
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months.[36] Unfortunately, this pilot did not demonstrate any benefits of screening, in part 
because at least half of affected boys do walk independently by that age.[37] Then, in 1990, with 
support from the Muscular Dystrophy Group (MDG) of the United Kingdom (UK), Wales began 
to screen infant boys for DMD by measuring CK on the newborn bloodspot. At that time, the 
Wales NBS program only tested for phenylketonuria (PKU) and hypothyroidism, both of which 
require immediate treatment. The decision was to make DMD optional and to require a separate 
consent “because the disease is untreatable, and there has been uncertainty about the effects on 
the family of such an early diagnosis.”[38 at p. 550]  
Although the Wales DMD program was not the first to screen for DMD, it was the longest 
running program (1990-2011) and it collected both clinical and psychosocial data.[39] In the first 
3 years, 34,219 boys were screened and nine affected boys were identified. In their first report, 
Bradley and colleagues noted that 8 of 9 families were satisfied with the process.[40]  
Experience with the first few screen-positive families led the program team to modify their 
protocol that then remained stable for the rest of the duration of the program. The family who 
was not satisfied had been informed at 2-3 weeks, earlier than in the program that developed 
subsequently, and their experiences helped the screening team to settle on a program of delayed 
return of results accompanied by a clear explanation about the purpose of follow-up testing and 
the provision of psychosocial support during the process. The protocol delayed recontacting the 
family about a positive screen until 4-6 weeks of age, with discussion in advance between the 
laboratory, the local pediatrician and the family's primary health care team, especially the health 
visitor. When contact was established, the parents were informed of the results and the need for a 
second sample to confirm or refute the risk of neuromuscular disease.  If the parent(s) consented 
to a repeat bloodspot, a system was in place to minimize delays in testing, reporting of results, 
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and arranging for a medical consultation[38]—all done with provision of on-going support 
involving the primary care team and (for much of the program) the Muscular Dystrophy Group-
supported Family Care Officer or a successor, a National Health Service-employed equivalent. 
Overall, in the 21 years that the program ran in Wales, approximately 94% of families of 
male infants agreed to screening, with 145 cases having an initially raised CK activity (at least 
250 U/l) and at follow-up, at ~6 weeks of age, this had returned to normal in 79 but remained 
elevated in the other 66 infants. Of these boys, 56 had DMD, five had Becker muscular 
dystrophy and the other five had different, rare muscle disorders.[39]  
Most parents of children affected with DMD in Wales believed the benefits of early 
screening outweighed the harms for the child and family, in part because it avoided the 
diagnostic odyssey.[26,41] Although the Wales data are reassuring, in that most parents 
expressed satisfaction, the data do not provide proof that it is in an affected boy’s best interests 
for his parents to have this information before he becomes symptomatic. Although 10 NBS 
programs have screened for DMD over the past 40 years, only one country (Belgium) continues 
to do so.[31] Despite waning support internationally, surveys of US pregnant women and parents 
of children affected with DMD, Becker muscular dystrophy and SMA show very strong  support 
for pre-symptomatic screening for DMD, although a significant minority (34.8%) thought NBS 
for DMD should require parental consent.[42] In 2007, the Centers for Disease Control and 
Prevention (CDC) funded two studies to evaluate uptake for DMD screening. In Ohio, DMD 
screening was offered with NBS,[31] and in Georgia, DMD screening was offered at 
approximately 12 months of life.[43] In both programs, samples with elevated CK measurements 
had genetic testing done without an additional sample or additional permission sought. Uptake 
was much higher in newborns when it was done as an add-on test to the neonatal blood spot. 
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(Ohio). Likewise in Germany, uptake was much lower when parents were offered DMD 
screening that required a separate blood sample at 6 weeks.[44]   
There are significant differences between the Wales program and how NBS for DMD would 
be conducted in the US.[45] First, NBS bloodspots in Wales are collected at 4-5 days, usually by 
a community midwife in the family’s home, allowing more time for deliberation. In the US, 
bloodspots are collected between 24-48 hours after birth, before the woman is discharged from 
the hospital. Average CK levels tend to run higher in the first two days of life, so depending on 
the cut-off, the US program will have to do follow-up testing on a larger percentage of 
infants.[30,31] Second, NBS for DMD in Wales was optional and required a separate consent.  
US advocates seek to incorporate CK measurements into the universal NBS programs which are 
mandatory and performed without consent (often without explanation[46-48]) despite the fact 
that symptoms do not usually present in infancy and supportive treatment is not needed then. 
Third is the timing for addressing a positive screen. In Wales, an elevated CK level was not 
reported back for four to six weeks which gave parents time to adjust to having a new baby, a 
practice that is consistent with the optional nature of screening newborns for a condition that will 
usually not present for years and does not require immediate treatment. In the US, an elevated 
CK would most likely lead to reflexive genetic mutation analysis, similar to the process used for 
cystic fibrosis screening where an elevated immunoreactive trypsinogen measurement on the 
newborn blood spot automatically triggers genetic testing.[31] This reduces parental control over 
the process which further supports a robust consent process at the time the sample is collected. 
 Early diagnosis would be less controversial if all agreed that treatment needed to be started 
before a clinical diagnosis is usually made. Recent data show that boys with DMD do express 
delays in early childhood as measured by the Bayley III scales of infant and toddler 
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development,[49] and that the gap increased with time.[50] If treatments were approved in this 
age group, the arguments that support screening newborns would be significantly strengthened. 
While some neurologists now support starting steroids earlier, perhaps as young as age 2 based 
on a single study involving five boys,[51] the guidelines support starting steroid treatment after 
motor skills plateau at approximately 4-6 years of age.[52-54] The long-term risks of starting 
corticosteroids in pre-school children have not been well-established. Treatment with Exondys 
51 (eteplirsen) to slow the decline in mobility of  patients who have a confirmed mutation of the 
dystrophin gene amenable to exon 51 skipping was approved by the US Food and Drug 
Administration (FDA) in September 19, 2016.[55]  All of the studies reviewed by the FDA 
involved boys over the age of 7 years,[56] an age at which virtually all boys have been 
diagnosed, weakening the argument for the need for diagnosis in the newborn period.  Further 
arguments against including DMD in NBS occured on that same day, when Robert Califf, the 
FDA commissioner, made public a report that he had written on September 16, 2016 in which he 
argued for retracting the 2013 DMD study by Mendell and colleagues[57] that gave greatest 
support for the drug’s approval.[58] Califf reiterated this position in a letter to the editor in the 
Annals of Neurology.[59]  Despite the controversy, the drug is currently approved, although 
continued approval for this indication is contingent upon verification of a clinical benefit in 
confirmatory trials. As such, whether there is an effective treatment for the 13% of boys who 
may benefit from skipping exon 51 remains an open question. 
 
  
Pompe Disease 
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Pompe disease is an autosomal recessive neuromuscular disorder that can be identified in 
newborns by measuring acid alpha-glucosidase (GAA) activity in blood or tissues. One-third of 
children identified will present with the classic form which has onset in infancy but the 
remaining two-thirds will present later.  The classic or infantile form is characterized by 
prominent hypotonia, muscle weakness, motor delay, feeding problems, and respiratory and 
cardiac insufficiency, some of which may be present even at birth.[60] Without treatment, life 
expectancy is less than one year. Approximately 2/3 of cases are late onset, presenting at variable 
times from several months of life to several decades. It is characterized by progressive, 
debilitating, and often life-threatening musculoskeletal, respiratory, and cardiac symptoms. It 
may be restricted to one organ or may affect all three. Unfortunately, genotype does not fully 
predict phenotype. 
 Treatment for Pompe disease consists of enzyme replacement therapy (ERT).  Several 
ERTs have been tried in patients with Pompe disease since 1967, but it was only in the early 
2000s that ERT with recombinant human alpha-glucosidase derived from rabbit milk or Chinese 
hamster ovary cells was successfully introduced and evaluated.[61] Within a few years, ERT for 
Pompe disease was approved in Europe, the US, Canada, and Japan.[62] 
The first program of NBS for Pompe disease began in Taiwan in 2005 as a research 
protocol that required parental consent.[63] After showing that screening was feasible and that 
children with infantile onset Pompe disease benefited from early initiation of ERT, Taiwan 
incorporated Pompe disease screening into their traditional screening programs in 2008.[64] 
Because parents must pay for a portion of the test, written parental consent is still required.[64] 
Over 90% consent. No data about psychosocial outcomes have been reported.  
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Supporters in the US argued to include Pompe disease in mandatory NBS programs for 
early screening because ERT reduces morbidity in those with infantile onset Pompe disease. In 
2008, Pompe disease was nominated for inclusion in the RUSP. The ACHDNC internal 
nomination and prioritization workgroup (hereinafter referred to as Workgroup) found its 
nomination premature.[65] The Workgroup expressed concern about the screening test because 
Taiwan’s pilot data published in 2005 revealed a high false positive rate. It also commented on 
the lack of prevalence data about infantile versus later onset disease, benefit of early diagnosis, 
and treatment and cost-effectiveness.[65] In May 2013, with more data from Taiwan, the 
Discretionary Advisory Committee for Heritable Disorders in Newborns and Children, which 
temporarily followed the ACHDNC, recommended the addition of Pompe Disease to the 
RUSP,[66] although it was not approved by the HHS Secretary until March 2015.[67] With HHS 
approval, one expects US states to add this condition to their NBS panels relatively quickly.  
Even before HHS Secretary endorsement, Missouri had already begun NBS for Pompe in 
2013 and Illinois in 2014. Pompe screening in Missouri began with a pilot program with IRB 
approval but without the requirement of getting parental consent. In the first published report 
from the US to-date, the Missouri public health department described screening 43,701 samples 
in the first 6 months:  
Among the newborns who screened positive for GAA deficiency (Pompe), 3 were 
diagnosed with the infantile form of the disease, 3 were classified as late-onset, 2 are 
currently classified as a genotype of unknown significance/onset, 2 had a 
pseudodeficiency, and 3 were found to be carriers.[68 at p. 174]  
 
It is not clear how those with late-onset genotypes and those with genotypes of unknown 
significance will be followed over the long-term.   
The decision to include Pompe disease in the RUSP is controversial for several reasons.  
The main controversy is that most (approximately 2/3) of individuals will be asymptomatic, 
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often for years or decades, and there is no consensus on when to begin treatment for those with 
non-infantile forms of the disease. This means that screening for Pompe disease challenges 
public health screening criteria. It also contradicts US pediatric genetic screening guidelines 
which strongly discourage testing children for adult onset conditions.[2-5,7-11]  Inclusion of 
Pompe in the RUSP is also controversial because of disagreements about the proper role of ERT. 
First, ERT for infantile onset Pompe disease, like steroids for DMD, delays morbidity but is not 
curative, and many affected infants end up ventilator-dependent regardless.  Second, ERT may 
lose effectiveness as patients develop antibodies to the enzyme, and it is relatively ineffective for 
the 20% with null alleles, who do not produce cross reactive immunological material (that is, 
CRIM negative status) because those with effectively no protein are more likely to generate 
antibodies to the ERT, which then block its effectiveness. Third, ERT does not cross the blood 
brain barrier and so has no impact on preventing or modifying neurological symptoms.[69]). 
In August 2016, the ACHDNC heard an update from the Missouri public health 
department about Pompe screening.[70] As of July 15, 2016, Missouri had screened 
approximately 276, 000 births and had confirmed 34 cases of Pompe disease with 7 infantile, and 
the rest late-onset or of unknown status. Six of the 7 infant cases were CRIM positive, but all 
were started on ERT, even the infant who was CRIM negative.  The rest are being followed.[70]  
Jennifer Kwon, a pediatric neurologist from New York discussed the status of long-term clinical 
follow-up that is a coordinated effort between the Newborn Screening Translational Research 
Network and the states in addition to the Genzyme registry.[71] She noted that there are ongoing 
efforts to clarify genotype-phenotype correlations, but that many questions persist including how 
frequently to follow these individuals with late-onset pompe disease genotypes and how to 
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respond to isolated abnormalities like an elevation of CK or complaints of fatigue or weakness in 
a person with a late onset genotype.[71]  
Although the ACHDNC recommended the inclusion of Pompe disease in the RUSP, one 
might argue that Pompe disease, like DMD, should not be included in the mandatory NBS 
program (tier 1) but, rather, should require a more robust consent process because 2/3 of 
individuals will have late onset presentations and we do not have a robust infrastructure to deal 
with them.  Rogers, the Missouri public health department official explained to the ACHDNC 
that there are no medical management guidelines/practices for the asymptomatic patient.  She 
expressed concern that those individuals at risk of becoming lost to follow-up.[70] There is also 
the concern of the psychosocial impact of becoming “patients in waiting”;[72] that is, patients 
with a genotypic diagnosis that may present at any time. Moreover, even for the infantile form, 
more needs to be studied regarding the use of ERT in CRIM negative children and long-term 
efficacy in CRIM positive children.  Other states may want to wait until additional data are 
available from Missouri.  
 
 Spinal muscular atrophy (SMA)  
SMA is an autosomal recessive neuromuscular disorder caused by mutation in the survival 
motor neuron (SMN) gene.  There are, in fact, two distinct but virtually identical SMN genes, 
SMN-1 and SMN-2.  In 95% of cases of SMA, there is the homozygous absence of the SMN1 
exon 7.  SMN2 produces less full-length transcription than SMN1, but the number of copies of 
SMN2 modifies the clinical course.[73] 
SMA is characterized by muscle weakness and atrophy due to loss of anterior horn cells in 
the spinal cord and brainstem nuclei. It has variability in onset and severity, although 60% 
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present in the first six months of life with SMA Type 1 (Werdnig-Hoffmann disease). SMA Type 
1 is the most severe, and most children are unable to sit or achieve any motor milestones. 
Another 20% have SMA Type 2 (Dubowitz disease) which presents between 6-18 months. These 
children can sit independently but rarely walk and usually live only until young adulthood. Type 
3  (Kugelberg-Welander) presents after 18 months and  Type 4  presents in adulthood. Both 
Types 3 and 4  have normal life expectancy. While severity does correlate with number of copies 
of SMN2, variability has been seen, even between siblings, presumably due to genetic 
modifiers.[73] 
Respiratory failure is the main cause of mortality in children with SMA Type 1.  While 
tracheostomy and invasive ventilation can prolong life, it also takes away any chance for oral 
communication and there has been a move to promote quality of life with noninvasive 
respiratory support. Nutritionally, children with SMA Type 1 often require gastric tube feedings. 
They also have orthopedic complications like scoliosis which can worsen respiratory function. 
Children with milder forms of SMA also suffer from significant fatigue which can interfere with 
walking and quality of life. 
When SMA was evaluated by the ACHDNC in 2008, it was determined to be too premature 
as no effective treatments existed.[74] There were only supportive treatments like g-tubes and 
noninvasive respiratory modalities to preserve the ability to speak. The ACHDNC requested that 
educational material be developed and small programs be piloted. The only pilot SMA NBS 
program to date was scheduled for Utah and Colorado,[75] but in the end recruited only in Utah 
where recruitment was slow. Parental consent was required and led to low uptake (Jeffrey 
Botkin, personal communication, April 2016). In December 2016, Nusinersen received global 
approval for the treatment of SMA for both children and adults.[76]  Nusinersen is an antisense 
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oligonucleotide drug that must be administered intrathecally. What is not known is whether 
adverse events become worse over time or more prevalent and what other long-term toxicities 
may develop.[76,77] Also under development by Avexis is a gene transfer candidate AVXS-101 
for the treatment of SMA-1.[77,78] In September 2016, the European Medicines Agency (EMA) 
granted Avexis access into its PRIority MEdicines (PRIME) program based on data from both 
preclinical evaluations and the ongoing Phase 1 clinical trial of AVXS-101.[79] 
Even before an effective treatment was available, there was strong support for SMA NBS in 
parents of boys affected with DMD, Becker muscular dystrophy and SMA, although a significant 
minority supported requiring parental consent.[42] One would expect even greater support now 
that there is an effective treatment, although there are still good reasons to require parental 
consent; namely, that 20% will not present until adulthood and that the treatment is quite new so 
that there are many unknowns regarding how long it will be effective and the risks of intrathecal 
administration. On March 7, 2017, CureSMA, in partnership with the SMA Newborn Screening 
Coalition, announced it had re-submitted a request that ACHDNC include SMA in the 
RUSP.[80] While ACHDNC may vote for its inclusion, ideally it would require parental consent 
to opt-in to screening (tier 2), pending further study of the therapies. 
 
When and why consent is needed 
 The debate about whether parents should give permission for newborn screening is as old 
as newborn screening itself.[2]  Those who support seeking parental permission argue that it 
demonstrates respect and increases parental awareness in the event of a positive test; those who 
object argue that the benefit-risk ratio justifies a more directive approach, that too much 
information would have to be given for consent to be “genuine”, and that consenting 
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immediately post-partum is not conducive to a considered decision.[81]  However, as states 
move from screening for a few conditions in which treatment is needed urgently to prevent 
morbidity and mortality to the use of platform technologies, the conditions now include disorders 
that do not require emergency treatment and in fact may not even have an effective treatment. 
Grosse and colleagues persuasively argue that expansion of state newborn-screening panels  
from public health emergencies to public health  services should reopen the question of parental 
involvement in these decisions.[82] That is, as we move away from conditions that require 
immediate treatment to prevent serious morbidity and mortality to conditions  that may not 
present immediately or for which treatment is not clearly effective, we should move away from a 
mandatory model and re-consider what role parents should play in deciding whether or not to test 
their children.   
In the US, there is consensus, albeit not unanimous, that parents should be informed about 
screening and that provisions should exist for them to opt-out, but that the presumption should be 
to screen when the condition meets the traditional criteria of a public health emergency.[82]  The 
justification for this is that screening is in the best interest of children.[9-11] For conditions that 
are not public health emergencies, there is more support for a more robust consent process:  
parents should be informed about screening and then be empowered to deliberate about whether 
they are the sort of parent who would want to know if their newborn infant had a serious 
condition that may or may not present in childhood, and may or may not be effectively treatable. 
The rationale is that educating parents and promoting deliberation empowers parents to do what 
they perceive to be best for their child and their family. 
In numerous reports, the Wales group spoke of the importance of the informed consent 
process, even after DMD went from a research pilot (1990-1998) to a program funded by the 
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health authority (1998-2011). While the Wales researchers justified screening for its potential 
benefits which include “the avoidance of distressing diagnostic delays, enabling the family to 
plan for the future in practical ways, including choice in future pregnancies, and the offer of 
physiotherapy at an early stage”,[38 at p 550] they also acknowledged the uncertain effect on the 
family of an early diagnosis for an incurable disease with the benefit: risk calculation dependent 
on how the family weighed the value of the early knowledge, the ability to prepare, and the 
avoidance of a diagnostic odyssey against the value of ‘blissful ignorance’ until the child 
developed symptoms that were recognized as requiring investigation. The robust stepwise 
consent process was designed to empower parents because it was not clear that NBS served the 
child’s best interest.  
Despite the steps taken, the Wales team still questioned whether parents were giving an 
informed and voluntary consent? The 94% consent rate and the detection of a few families very 
distressed by the diagnosis led the screening team to suspect that the uptake rate was inflated by 
routinization and, perhaps, parental compliance with what may have been perceived as a 
professional recommendation. Pilot studies were conducted to look into enhancing the consent 
process. For example, collecting an additional blood spot card for the DMD test emphasized that 
this test was different from the others and that it needed to be considered differently. This 
empowered the midwife to recommend screening for PKU and hypothyroidism without 
reservation, and to give a more muted recommendation to screening for DMD by emphasizing 
both risks and benefits. This altered the pattern of communication between professional and 
parent (usually mother) in a helpful fashion, increasing satisfaction with the process of consent, 
while reducing uptake to 78%, a level suggesting greater engagement in the decision.[83] 
Unfortunately it was never adopted into the program, but it does offer insight into how consent 
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can be performed in a way that promotes greater choice and more informed deliberation. In 
Germany, when testing was moved to the six-week well child visit and required a new sample be 
collected, less than 15% of infants were screened.[44] One must question then whether parents 
truly want testing, despite the surveys,[42] when even small barriers decrease uptake by almost 
80% (from 94% in Wales to 15% in Germany). Separating tier one and tier two testing in time 
and sample may lead to a more considered decision.[84] 
The concept of a two-tiered newborn screening system has been supported by several US 
groups.[5,6,8]  When screening for a neuromuscular life-limiting disorder which does not require 
immediate clinical intervention (DMD) or which identifies many with later onset conditions 
(Pompe, less so SMA), informing parents, promoting deliberation, ensuring appropriate 
infrastructure for long-term follow-up, and obtaining their consent is critical to screen ethically.  
The ACHDNC should seriously consider the benefits of a two-tiered NBS program for these 
neuromuscular disorders and other conditions that challenge public health screening criteria.  
 
Consent is necessary but not sufficient 
 A robust consent process is necessary but, by itself, is not sufficient to achieve an 
ethically sound NBS program. Tier 2 conditions require an accessible infrastructure to support 
those families who receive a positive diagnosis and to follow those children even though 
symptoms may not develop for many years or decades. In Wales, the health system partnered 
with the MDG (now the Muscular Dystrophy Campaign) to ensure counseling and support, 
although funding for this became difficult once MDG support was no longer available.   
 Taiwan has a national health insurance scheme which should simplify Pompe follow-up, 
although how successful this will be for those who develop symptoms later on in life is 
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unknown. Internationally, Genzyme, a Sanofi company (Cambridge, MA). started a long-term 
Pompe disease registry in 2004, but how and whether this will successfully track those who are 
asymptomatic for years or decades is still to be seen.[85] Imagine a 35-year-old diagnosed with 
Pompe disease at birth but without symptoms until age 30.  The patient might not “remember” 
his diagnosis as a neonate, or he may never have been told about it, and most primary care 
physicians will be unaware of the registry. The patient, then, will most likely undergo a 
diagnostic odyssey before he is re-identified as having Pompe disease. This “lost” time may be 
detrimental to his health. 
Thus, before public health programs can justify screening for a condition in which most 
patients will be asymptomatic for years or decades, long-term follow-up infrastructure and 
coordination with the medical home (a team-based health care delivery model led by a primary 
health care provider) will be necessary.[86] Coordination between NBS and the medical home, 
proposed back in 2000, is consonant with the mission of NBS programs which have always 
prided themselves in being more than a test and providing a comprehensive system.[6] Although 
implementation will be challenging in a fragmented health care system as exists in the US,  it is 
irresponsible to add these conditions without the appropriate resources and infrastructure. One 
could further argue that these conditions should not be added (even to Tier 2) unless there are 
research protocols in place to enroll children who screen positive (with parental consent) in order 
to more quickly advance the science that could justify their inclusion in screening platforms in 
the first place. 
 
Conclusion 
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There are many advocates who support expanding NBS to include diseases that do not 
clearly meet public health screening criteria. Creating a two-tiered NBS program would respect 
professional ethics and parental autonomy and would promote public trust; disorders can be 
moved from Tier 2 to Tier 1 as evidence accumulates to establish the overall direct benefit of an 
early diagnosis through screening. However, screening for second-tier conditions should only be 
offered if the necessary infrastructure and support services are in place to support those families 
who receive a positive diagnosis regardless of the time delay from diagnosis to clinical 
presentation. 
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